Martin Gartland

1.9k citations

19 papers · 866 indexed · 1 hit paper · h-index 11

Virology top 1%
- HIV Research and Treatment 14
Infectious Diseases top 2%
- HIV/AIDS drug development and treatment 17
- HIV/AIDS Research and Interventions 8
Emergency Medicine top 2%
- HIV-related health complications and treatments 5
Hepatology
- Hepatitis C virus research 3
Orthopedics and Sports Medicine
Molecular Biology
- Biochemical and Molecular Research 3
Epidemiology
- Herpesvirus Infections and Treatments 2
- Cytomegalovirus and herpesvirus research 1

Co-authors: Michael Aboud Brian Wynne Mark Underwood Lesley Kahl Kati Vandermeulen Kimberly Y. Smith Elizabeth A. Blair Chien‐Ching Hung
Cited by: Virology Infectious Diseases Emergency Medicine
Partner nations: United Kingdom Spain United States

In The Last Decade

Martin Gartland

18 papers receiving 843 citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2018 Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Peers

Countries citing papers authored by Martin Gartland

Since Specialization

Citations

This map shows the geographic impact of Martin Gartland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Gartland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Gartland more than expected).

Fields of papers citing papers by Martin Gartland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Gartland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Gartland. The network helps show where Martin Gartland may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Martin Gartland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Martin Gartland Line = papers co-authored together Martin Gartland links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work
1	Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile Luise Rogg,Mark Underwood,Nathan Hanan,José Castillo‐Mancilla,Lesley Kahl,Fiona Halliday,Gabriela Ghita,Jerry Jeffrey,Stephen Byrne,Tsukasa Onodera,Joseph Horton,Martin Gartland	2025	0
2	A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937 Paul Benn,Ying Zhang,Lesley Kahl,Thomas Greene,Veronica Bainbridge,Cindy Fishman,Bo Wen,Martin Gartland	2023	7
3	Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants Ying Zhang,Mark Johnson,Samit R. Joshi,Parto Yazdani,Joyce Zhan,Bo Wen,Veronica Bainbridge,Martin Gartland,Max Lataillade	2023	1
4	Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254 Christoph D. Spinner,Franco Felizarta,Giuliano Rizzardini,Patrick Philibert,Essack Mitha,Peré Domingo,Christoph Stephan,Michelle DeGrosky,Veronica Bainbridge,Joyce Zhan,Teodora Pene Dumitrescu,Jerry Jeffrey,Jianfeng Xu,Fiona Halliday,Jianjun Gan,Mark R. Johnson,Martin Gartland,Samit R. Joshi,Max Lataillade	2022	15
5	Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study Jean van Wyk,Faïza Ajana,Fiona Bisshop,Stéphane De Wit,Olayemi Osiyemi,Joaquín Portilla,Jean‐Pierre Routy,Christoph Wyen,Mounir Ait‐Khaled,Maria Cláudia Nascimento,Keith A. Pappa,Ruolan Wang,Jonathan Wright,Allan R. Tenorio,Brian Wynne,Michael Aboud,Martin Gartland,Kimberly Y. Smith	2020	171
6	Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study) Jean van Wyk,F. Ajana,Fiona Bisshop,(unknown),Y. Osiyemi,Joaquín Portilla,Jean‐Pierre Routy,Christoph Wyen,Mounir Ait‐Khaled,M. C. Nascimento,Keith A. Pappa,Rachel Y. Wang,Jackson Wright,A. Tenorio,Brian Wynne,Michael Aboud,Martin Gartland,Kate Smith,Y. El-Bahy	2020	6
7	Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis Joseph J. Eron,Chien‐Ching Hung,Jean‐Guy Baril,Jihad Slim,Vicenç Falcó,Johannes R. Bogner,Franco Maggiolo,Anthony Mills,Jörg Sievers,Choy Man,Rimgaile Urbaityte,Mark Underwood,Allan R. Tenorio,Keith A. Pappa,Brian Wynne,Justin Koteff,Martin Gartland,Kimberly Y. Smith,Michael Aboud	2020	15
8	Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials Jean van Wyk,Chloe Orkin,Rafael Rubio,Johannes R. Bogner,David Baker,Marie-Aude Khuong-Josses,David Parks,Konstantinos Angelis,Lesley Kahl,Jessica Matthews,Ruolan Wang,Mark Underwood,Brian Wynne,Maria‐Claudia Nascimento,Kati Vandermeulen,Martin Gartland,Kimberly Y. Smith	2020	32
9	Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies Michael Aboud,Chloe Orkin,Daniel Podzamczer,Johannes R. Bogner,David Baker,Marie-Aude Khuong-Josses,David Parks,Konstantinos Angelis,Lesley Kahl,Elizabeth A. Blair,Kimberly K. Adkison,Mark Underwood,Jessica Matthews,Brian Wynne,Kati Vandermeulen,Martin Gartland,Kimberly Y. Smith	2019	77
10	Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial Michael Aboud,Richard Kaplan,Johannes Lombaard,Fujie Zhang,José A. Hidalgo,Elmira Mamedova,Marcelo Losso,Ploenchan Chetchotisakd,Carlos Brites,Jörg Sievers,Dannae Brown,Judy Hopking,Mark Underwood,Maria Cláudia Nascimento,Yogesh Punekar,Martin Gartland,Kimberly Y. Smith	2019	104
11	Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study Michael Aboud,Richard Kaplan,Johannes Lombaard,F. Zhang,José A. Hidalgo,Elmira Mamedova,Marcelo Losso,Ploenchan Chetchotisakd,Carlos Brites,Jörg Sievers,Dannae Brown,Judy Hopking,Mark Underwood,M. C. Nascimento,Martin Gartland,K. Smith,C. R. Steinhart,José M. Gatell	2019	5
12	Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies Joseph J. Eron,Chien‐Ching Hung,Jean‐Guy Baril,Jihad Slim,Vicenç Falcó,Johannes R. Bogner,Franco Maggiolo,Anthony Mills,Jörg Sievers,Choy Man,Alexander Currie,Mark Underwood,Allan R. Tenorio,Keith A. Pappa,Brian Wynne,Justin Koteff,Martin Gartland,Kimberly Y. Smith,Michael Aboud,Alistair G. Paice	2019	3
13	2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies Alan Oglesby,Kostas Angelis,Yogesh Punekar,Vasiliki Chounta,Antonio Antela,Jessica Matthews,Lesley Kahl,Martin Gartland,Brian Wynne,Miranda Murray,Jean A van Wyk	2019	2
14	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesbreakdown → Josep M. Llibre,Chien‐Ching Hung,Cynthia Brinson,Francesco Castelli,Pierre‐Marie Girard,Lesley Kahl,Elizabeth A. Blair,Kostas Angelis,Brian Wynne,Kati Vandermeulen,Mark Underwood,K. Smith,Martin Gartland,Michael Aboud	2018	243
15	Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health Grace A. McComsey,Sergio Lupo,David Parks,Mónica Coronado Poggio,Joseph de Wet,Lesley Kahl,Kostas Angelis,Brian Wynne,Kati Vandermeulen,Martin Gartland,Michael Cupo,Michael Aboud	2017	43
16	96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study Graeme Moyle,Hans‐Jürgen Stellbrink,Juliet Compston,Chloe Orkin,José Ramón Arribas,Peré Domingo,Catherine Granier,Helen Pearce,Sangeeta Sedani,Martin Gartland,(unknown)	2013	52
17	Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies Michael Maguire,Martin Gartland,Sarah Moore,Andrew Hill,Margaret Tisdale,Richard Harrigan,Jőrg‐Peter Kleim	2000	63
18	Avanti 1: Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Zidovudine plus Lamivudine versus Zidovudine plus Lamivudine plus Loviride in HIV-Infected Antiretroviral-Naive Patients Josep M. Gatell,J Lange,Martin Gartland,(unknown)	1999	17
19	Vectors with multiple insertion sites for expression of cloned genes by T7 RNA polymerase: expression of a peptide from EBV thymidine kinase (TK) M. Mackett,E. Littler,R. Michael,Martin Gartland,J. R. Arrand	1990	10

About Martin Gartland

Martin Gartland is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 19 papers that have together received 866 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (14 papers), HIV/AIDS Research and Interventions (8 papers), HIV-related health complications and treatments (5 papers), Biochemical and Molecular Research (3 papers), Hepatitis C virus research (3 papers), Herpesvirus Infections and Treatments (2 papers) and Cytomegalovirus and herpesvirus research (1 paper). The work is most often cited by research in Virology (634 citations), Infectious Diseases (794 citations) and Emergency Medicine (262 citations). Martin Gartland has collaborated with scholars based in United Kingdom, Spain and United States. Frequent co-authors include Michael Aboud, Brian Wynne, Mark Underwood, Lesley Kahl, Kati Vandermeulen, Kimberly Y. Smith, Elizabeth A. Blair, Chien‐Ching Hung, Cynthia Brinson and Josep M. Llibre.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact